My wife was treated for AML Sub-type M2 with complex cytogenetics including Delete 5, Delete 7, Delete 12 and Monosomy 17 chromosomal karyotypes using 7/3 induction therapy (Cytarabine and Daunorubicin). We know that prognosis is very unfavorable when associate with these specific deletions. She also suffered from Colitis, Vasculitis, and a form of pleurisy after chemo. After 5 weeks post release from hospital following indications of a complete remission, she is now experiencing pneumonia, bone pain, peeling skin, and intermittent fever. She has received 2 units of red blood last weeks. Is it time to forego re-induction therapy and proceed to alternatives, or switch to lower dose maintenance chemo provided on an outpatient basis to provide some extended life expectancy?